PNH: Current Thinking on the Disease, Diagnosis and Treatment. What is PNH? 7/6/2009. Paroxysmal sudden onset Nocturnal
|
|
- Brooke Holly Ellis
- 5 years ago
- Views:
Transcription
1 PNH: Current hinking on the Disease, Diagnosis and reatment Jaroslaw Maciejewski, MD, PhD Cleveland Clinic Carlos M. de Castro, MD Duke University Medical Center Paroxysmal sudden onset Nocturnal occuring at night (or early in morning upon awakeneing) Hemoglobinuria What is PNH? Despite the name, most patients do not present this way. PAROXYSMAL NOCURNAL HEMOGLOBINURIA Estimated 4,000 6,000 patients in U.S. 1 5 year mortality: 35% 2 Diagnosed at all Ages Median age early 30 s 3,4 Quality of life diminished 5 Progressive disease 5 viving (%) Patients Surv Actuarial Survival From the ime of Diagnosis in 80 Patients With PNH 1 Age- and sex- matched controls Patients with PNH Years After Diagnosis he expected survival of an age- and sex-matched control group is shown for comparison (Hillmen et al 1995). In a patient population where ½ the patients have <30% clone, 1 in 7 patients died by 5 years (de Latour et al. Blood. 2008; 112: ) 1. Hill A et al. Blood. 2006;108(11): 290a. Abstract Hillmen, et al. N Engl J Med. 1995;333: Nishimura JI, et al. Medicine. 2004;83: Socié G et al. Lancet. 1996;348: Hill A et al. Br J Haematol. 2007;137:
2 CAUSES OF PNH WHA CAUSES PNH? he mutation in the PIG-A gene in a hematopoietic stem cell leads to a defect in the production of an anchor protein that ties other proteins to the cell surface. SEM CELLS Egg E g g Sperm Embryonic Stem Cell Egg or Sperm Blood Muscle Nerve Etc. Somatic Stem Cells he Cells of Each Specific Organ 2
3 A BLOOD SEM CELL CAN GIVE RISE O ALL HE CELLS OF HE BLOOD LYMPHOCYES Blood stem cell B LYMPHOCYES ERYHROCYES GRANULOCYES MONOCYES after Rosse, modified PLAELES IN PNH, A SINGLE MUAION OCCURS IN ONE BLOOD SEM CELL MARROW SEM CELL LYMPHOCYES B LYMPHOCYES ERYHROCYES GRANULOCYES MONOCYES ALERED GENE PLAELES EVOLUION OF PNH IN MARROW NORMAL CLONES ABNORMAL CLONE 3
4 PNH: PAHOPHYSIOLOGY Stem cells PIG-A GPI-anchored proteins MUAIONS IN PIG-A GENE IN PNH Somatic mutations in PIG-A gene NH 2 NH 2 Extracellular space COOH Lack of GPI linked proteins Is responsible for symptoms Hemolysis hrombosis Escape from immune attack and selection Cytoplasm COOH Lack of surface GPI- Anchored Proteins GPI-LINKED PROEINS Examples: Decay accelerating factor CD59 Membrane inhibitor or reactive lysis CD58 LPS receptor CD14 LFA-3 CD59 CD48 Leukocyte alkaline phosphatase Acetyl choline estarase hy-1 Urokinase plasma receptor, UPAR CD177 (NA-1) And many more. 4
5 IMMUNE HEORY OF PNH EVOLUION Immune attack on hematopoietic cells Normal stem cell -cells PNH stem cell PNH PNH PNH PNH PNH Selective pressure Selective resistance WHA IS COMPLEMEN? Complement is a group of proteins that are part of our immune system. Complement circulates in an inactive form. A little bit of complement is always being activated spontaneously, especially at night. Many different events can activate complement including trauma, infection, stress, etc. Complement will attack certain bacteria by making pores in the surface of the bacteria. In PNH, activated complement will attack red cells causing them to lyse (burst) erminal Complement Activation Renders RBCs Susceptible to Hemolysis Normal RBCs PNH RBC CD59 Complement Activation Intact RBC Chronic Hemolysis Lysed PNH RBCs and free hemoglobin in the plasma 5
6 WHA HAPPENS WHEN RED CELLS HEMALYZE? he red cells are destroyed - anemia Hemoglobin is released into the plasma (the fluid part of blood) Some of the hemoglobin passes through the kidneys and into the urine leading to the dark color of the urine Loss of iron May lead to kidney damage in the long run Free hemoglobin binds nitric oxide What is nitric oxide? WHA IS NIRIC ACID? A gas produced by the body to regulate smooth muscle cells. An increase in free nitric oxide causes smooth muscle cells to relax. A decrease causes smooth cells to contract. Smooth muscle cells are in many tissue Blood vessel walls: ischemia, impotence Esophagus and GI tract: esophageal spasm, reflux, abdominal pain SYMPOMS OF PNH 6
7 CARDINAL SYMPOMS Hemolysis Propensity for blood clots (thrombosis) Decreased production of blood cells 65% of patients lived longer than 10 years and 48% longer than 15 years Predictors of decreased survival: -Development of low counts (relative risk of 5.5) -Occurrence of thrombosis (relative risk 10) -Development of MDS (relative risk of 19) In 50% of patients PNH does not affect their survival SIGNS AND SYMPOMS OF PNH Clinical Signs or Symptoms Incidence Rate (%) hrombosis Dyspnea Chronic Renal Disease stage % 66% 65% Abdominal Pain 57% Anemia Up to 100% Fatigue, impaired QOL 96% Hemoglobinuria 26% Dysphagia 41% Erectile Dysfunction 47% PNH - hrombosis 10% of PNH patients present with thrombosis (blood clots) Up to 40% will develop clots during the course of their disease. While approximately 1/3 of these clots are typical deep vein thrombosis, another 1/3 occur in the GI system (liver, spleen), and the last third are in unusual locations (CNS, dermal veins, arterial sites). Once a clot develops, there is a strong tendency towards developing further clots, even with anticoagulation. Once a thrombosis develops, the prognosis is grim. 7
8 hrombosis in PNH Arterial / MI Arterial / CVA 2% DV: leg 14% 18% Superficial 4% Cerebral 6% PE 7% DV: other 15% Hepatic / portal 16% Mesenteric / splenic 18% CVA, cerebrovascular accident; DV, deep vein thrombosis; MI, myocardial infarction PNH - hrombosis he cause of blood clots in PNH is still not clear. he role of prophylactic anticoagulation (warfarin) is controversial reatment of an acute thrombotic event may include clot busters lytic agents Anticoagulation is standard (warfarin, heparin, enoxaparin, etc.) In the past, bone marrow transplantation was strongly considered for a PNH patient if they developed a clot. Eculizumab appears to markedly reduce the incidence of blood clots DIAGNOSING PNH 8
9 DIAGNOSIS OF PNH Clinical symptoms/suspicion History of aplastic anemia Fatique anemia Hemolysis Sudden blood clots Dark urine AA/PNH syndrome Laboratory testing - Low blood counts - Hemolysis - LDH high - Haptoglobin low - Often low iron - Flow cytometry for PNH cells - Often high reticulocytes - Bone marrow exam Red cell production problem Hemolytic PNH Hemolysis- destruction problem CAUSES OF HEMOLYIC ANEMIA EXRINSIC CAUSES Immune mediated AIHA Drug induced Delayed transfusion rx PCH Cold agglutinin dz Microangipathic DIC P/HUS Valve hemolysis Other trauma (March, burns) Other causes Snake bites oxins Infusion of hypotonic sol n INRINSIC CAUSES Enzyme deficiencies G6PD Pyruvate kinase Others Hemoglobinopathies Sickle cell dz halassemia Unstable Hgb Membrane defects Hereditary spherocytosis Hereditary elliptocytosis Paroxysmal Nocturnal Hemoglobinuria (PNH) MEHODS OF HISORICAL INERES Ham est acidified serum lysis test Specific but not sensitive Sugar Water est serum in isotonic sucrose solution Sensitive but not specific Complement lysis sensitivity test lysis by antibody and limiting complement Defined PNH II (moderately abnormal) and PNH III (markedly abnormal red blood cells) 9
10 Flow Cytometry: Diagnostic est for PNH Perform on peripheral blood Use monoclonal antibodies against GPI-anchored proteins, such as CD59 or CD55 1,2 PNH blood cells (PNH clone) are cells missing GPI-anchored proteins 1 Parker, et al. Blood. 2005;106: ²Hall & Rosse. Blood. 1996;87: Fluorescent AERolysin (FLAER) FLAER binds to the GPI-anchor itself, rather than to a single protein such as CD55 or CD59 FLAER provides much greater signal noise and better accuracy than an antibody against a single target α-cd59 CD59 FLAER GPIlinked protein FLAER ypes of PNH 10
11 YPES OF PNH Primary hemolytic PNH No evidence for marrow failure Can evolve from AA Often primary disease Anemia solely due to hemolysis No benefit of immunosuppression AA/PNH syndrome Counts often depressed Marrow hypocellular May benefit from immunosuppressioni Usually a late complication of AA CLINICAL MODES OF DEVELOPMEN OF PNH Hemolysis Primary hemolytic PNH Aplastic anemia Secondary hemolytic PNH Aplastic anemia/pnh syndrome Bone marrow failure PNH CLONES IN BONE IMMUNE MEDIAED BONE -deficient granulocytes % of GPI CONROL AA MDS PNH MARROW FAILURE CD59PE Maciejewski et al Blood, 2000, BJH
PNH. PNH A study case 5/9/2012. PNH Current Thinking on the Disease, Diagnosis, and Treatment. Where have we been, where are we going?
PNH Current Thinking on the Disease, Diagnosis, and Treatment Where have we been, where are we going? Carlos M. de Castro, MD Duke University Medical Center PNH Case What is PNH? What causes PNH? Relationship
More informationPNH. What is PNH? 7/12/2016 PNH. What is PNH? 1 st published case report of PNH
AA-MDS Patient Conference Raleigh / Durham July 016 : Current Thinking on the Disease, Diagnosis, and Treatment What is? What causes? What are the clinical symptoms of? How is diagnosed? What are the long-term
More informationWhat is PNH? PNH: What it is Not 9/11/2015. What is Paroxysmal Nocturnal Hemoglobinuria?
9/11/15 PNH: Current Thinking on the Disease, Diagnosis, and Treatment Joseph H. Antin, MD Professor of Medicine Harvard Medical School Jock and Bunny Adams Chair in Hematology Dana-Farber/Brigham and
More information10/27/2017 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DANIEL LANDAU, MD PNH TYPICAL CASE
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Daniel Landau, MD Orlando Health: UF Health Cancer Center Hematologist/ Oncologist Orlando Health University of Florida Cancer Center Section Chief of Hematology/Oncology
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More information9/19/2017. PNH Understanding your diagnosis and treatment. Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria
August_20_2010US Patients Surviving (%) Paroxysmal Nocturnal Hemoglobinuria (PNH) PNH Understanding your diagnosis and treatment Hugo Castro-Malaspina, MD Memorial Sloan Kettering Cancer Center New York,
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Current Thinking On the Disease Diagnosis and Treatment Ilene Ceil Weitz, MD Associate Clinical Professor of Medicine Jane Anne Nohl Division of Hematology Keck-USC
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More information4/17/2018. Paroxysmal Nocturnal Hemoglobinuria: Paroxysmal Nocturnal Hemoglobinuria. Epidemiology. PNH Stem Cell.
Paroxysmal Nocturnal Hemoglobinuria: Understanding the Diagnosis, Complications and Treatment Options Iberia Romina Sosa, MD, PhD Assistant Professor of Medicine Baylor College of Medicine April 21, 2018
More informationNew Phase III Clinical Trial Enrolling Now
New Phase III Clinical Trial Enrolling Now Paroxysmal Nocturnal Hemoglobinuria (PNH) Designed for Patients 1. At least 18 years of age 2. With a primary diagnosis of PNH confirmed by high-sensitivity flow
More informationPNH PNH PNH 3/22/2016 PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH): Current Thinking on the Disease PATHOGENESIS OF PNH
3//1 PATHGENESIS F PIG-A gene Bone Marrow Failure Disease Scientific Symposium Rockville, March 17-1, 1 1 71 9 3 Paroxysmal Nocturnal Hemoglobinuria (): Current Thinking on the Disease 119 5 15 PRTEIN
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More informationSOLIRIS (eculizumab) Slide # 1. How do we treat PNH?
Treating PNH How do we treat PNH? Hemolytic anemia Iron, folic acid Transfusion Steroids Eculizumab Thrombosis Coumadin prophylaxis Acute treatment with lytic agents (clot busters) Anticoagulation therapy
More information3/31/2014 PNH. Jack Goldberg MD FACP. Clinical Professor of Medicine University of Pennsylvania
PNH Jack Goldberg MD FACP Clinical Professor of Medicine University of Pennsylvania 1 2 3 4 1 5 6 Historically Viewed as a Hemolytic Anemia Normal red blood cells are protected from complement attack by
More informationAbdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report
Received: 22 January 2018 Revised: 25 April 2018 DOI: 10.1002/ccr3.1771 Accepted: 9 June 2018 CASE REPORT Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for
More information7/14/2014. SOLIRIS (eculizumab) SOLIRIS PNH Clinical Studies. SOLIRIS Blocks Terminal Complement. 86% Reduction in LDH: TRIUMPH and SHEPHERD
Proximal Terminal Lactate Dehydrogenase (U/L) 7/1/1 SOLIRIS (eculizumab) Humanized First in Class Anti - C5 Antibody SOLIRIS (eculizumab) Human Framework Regions No mutations Germline SOLIRIS is a Complement
More informationSOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis
SOLIRIS (eculizumab) SOLIRIS is a Complement Inhibitor Indicated for the Treatment of Patients With PNH to Reduce Hemolysis SOLIRIS is the First and Only Approved Therapy for PNH SOLIRIS (eculizumab) [package
More informationSlide # 1. What is PNH and what is the long term outlook? Carlos M. de Castro, MD Duke University Medical Center. October 2012 AA&MDSIF Conference
PNH: Complications and Long-Term Issues Carlos M. de Castro, MD Duke University Medical Center October 2012 AA&MDSIF Conference PNH: Comlications and Long-Term Issues What happens to PNH patients? What
More informationDairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009
HAEMOLYTIC ANAEMIA Dairion Gatot, Soegiarto Ganie, Savita Handayani. Divisi Hematologi & Onkologi Medik Departemen Ilmu Penyakit Dalam FK-USU/RS H.Adam Malik Medan 2009 WHEN BY THEN Hb 9 g% transfusion
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More informationUnderstanding and Managing Long- Term and Late Issues in PNH. Outline
Understanding and Managing Long- Term and Late Issues in PNH AA & MDS International Foundation Regional Patient and Family Conference Cleveland, Ohio Ramon V. Tiu, MD Cleveland Clinic Taussig Cancer Institute
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Jun Ho Jang, M.D., Ph.D. Professor, Division of Hematology-Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea Contents 1. Disease
More informationCASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report
Malaysian J Pathol 2006; 28(2) : 107 112 CASE REPORT Assessing donor chimerism using flow cytometry in paroxysmal nocturnal haemoglobinuria after stem cell transplantation - a case report R Z Azma, MBBS,
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2014 (2014), Article ID 504318, 21 minipages. DOI:10.5171/2014.504318 www.ibimapublishing.com Copyright 2014 Pinar Tosun Taşar, Sevnaz Sahin, Asu
More informationEfficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort
BLOOD RESEARCH VOLUME 52 ㆍ NUMBER 3 September 2017 ORIGINAL ARTICLE Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean
More informationAcute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration
Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration Chun-Liang Lin 1, Chin-Chan Lin 1,Wen-Jyi Lo 2,Yu-Chien
More informationKey terms: aplastic anemia; complement inhibitors; paroxysmal nocturnal hemoglobinuria
Cytometry Part B (Clinical Cytometry) 94B:16 22 (2018) Original Article ICCS/ESCCA Consensus Guidelines to detect GPI-deficient cells in Paroxysmal Nocturnal Hemoglobinuria (PNH) and related Disorders
More informationeculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd
eculizumab, 300mg concentrate for solution for infusion (Soliris ) SMC No. (436/07) Alexion Pharma UK Ltd 8 October 2010 (Amended 11 July 2011) The Scottish Medicines Consortium (SMC) has completed its
More informationDana Alsulaibi. - Ahmad Almuhtaseb. - Tariq Al - Adaily
- 2 - Dana Alsulaibi - Ahmad Almuhtaseb - Tariq Al - Adaily This sheet will talk about 4 diseases that cause hemolytic anemia, best of luck! 1) Hereditary Spherocytosis Transferred through inheritance
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More information3 Ruba hussein Dr. ahmad Dr. ahmad
3 Ruba hussein Dr. ahmad Dr. ahmad The arrangement of this sheet differs from that of the record. Anemia of peripheral removal in which we are losing hemoglobin and RBCs mass and the two major Causes are:
More informationDiagnostic Approach to Patients with Anemia
J KMA Special Issue Diagnostic Approach to Patients with Anemia Seonyang Park, MD Department of Internal Medicine, Seoul National University College of Medicine E mail : seonpark@snu.ac.kr J Korean Med
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2018 Clinical Consequences of Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia: A Multidisciplinary Discussion PLUS
More informationBone Marrow Transplantation
Bone Marrow Transplantation Introduction Bone marrow is the spongy tissue inside all of your bones, including your hip and thigh bones. The bone marrow is like a factory that makes different types of blood
More informationرناد زكريا Dr. ahmad Dr. ahmad. P a g e 1
5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1 Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred
More informationPNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy
PNH Screening in Patients with Recurrence of Thrombosis during Anticoagulant Therapy PI: Prof. Anna Falanga Bergamo Italy Prof. Anna Falanga Page 1of 9 Introduction Scientific background Genetic basis
More informationAcknowledgments. Michael Brown Petra Muus for case reports
Current treatment strategy for PNH Jeff Szer Professor/Director, Department of Clinical Haematology & BMT Service The Royal Melbourne Hospital Australia Acknowledgments Michael Brown Petra Muus for case
More information9/19/2012. Case study. Case study PNH: A REVIEW AND AN UPDATE
PNH: A REVIEW AND AN UPDATE Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Case study A 37 year old man was referred to the hematology
More informationWARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. WARNING:
More informationGeneral Characterisctics
Anemia General Characterisctics Definition: anemia is a decrease in red blood cells. Happens due to underproduction, increased destruction or loss of red cells. Diagnosis of anemia: Hgb < 135 (men) Hgb
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More informationSlide # 1. PNH: Comlications and. Long-Term Issues. Long-Term Issues. What is PNH and what is the long term outlook?
PNH: Complications and Long-Term Issues Carlos M. de Castro, MD Duke University Center What happens to PNH patients? PNH: Comlications and Long-Term Issues What are the long-term complications of PNH and
More informationExamination Tests from Pathological Physiology. Pavel Maruna et al. Reviewed by: Prof. MUDr. Emanuel Nečas, DrSc. Prof. MUDr. Jaroslav Veselý, CSc.
Examination Tests from Pathological Physiology Pavel Maruna et al. Reviewed by: Prof. MUDr. Emanuel Nečas, DrSc. Prof. MUDr. Jaroslav Veselý, CSc. Authors: Prof. MUDr. Pavel Maruna, CSc. Doc. MUDr. Martin
More informationHEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC
HEMOLYTIC ANEMIAS Edited by: GR. Bahoush, MD. HEMOLYTIC ANEMIA Anemia of increased destruction Normochromic, normochromic anemia Shortened RBC survival Reticulocytosis - Response to increased RBC destruction
More informationIF YOU HAVE PNH, YOU ARE NOT ALONE. Take a closer look and take control of PNH
IF YOU HAVE PNH, YOU ARE NOT ALONE Take a closer look and take control of PNH Indication and Usage Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab) is indicated for the treatment of patients
More information7/26/2013. The Defect in PNH PNH: NEW DIRECTIONS IN PNH TREATMENT. Paroxysmal Nocturnal Hemoglobinuria: Survival
PNH: NEW DIRECTIONS IN PNH TREATMENT Jamile M. Shammo MD, FASCP, FACP Associate Professor of Medicine and Pathology Rush University Medical Center Chicago Paroxysmal Nocturnal Hemoglobinuria: Survival
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
The Oncologist Regulatory Issues: FDA FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria ANDREW DMYTRIJUK, KATHY ROBIE-SUH, MARTIN H. COHEN, DWAINE
More information1/26/12. Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY OBJECTIVES. Classically Different Topics but not so much
1/26/12 OBJECTIVES Selected Topics in Pediatric Hematology/Oncology COMPLEMENTOLOGY Chatchawin Assanasen MD Recognize implications of complement pathway diseases Signs and symptoms of PNH and ahus Complications
More informationSickle Cell Disease. Edward Malters, MD
Sickle Cell Disease Edward Malters, MD Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal
More informationFDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
FDA Report: Eculizumab (Soliris ) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria Andrew Dmytrijuk, Kathy Robie-Suh, Martin H. Cohen, Dwaine Rieves, Karen Weiss and Richard Pazdur
More informationTHE UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PATHOLOGY
THE UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PATHOLOGY INTRODUCTION TO ANEMIA Third year medical students First semester 2018/2019 Dr. RBC DISORDERS Lecturer: Dr. Tariq Al-Adaily Email: TNALADILY@ju.edu.jo
More informationSoliris (eculizumab) For the Treatment of PNH to Reduce Hemolysis
Soliris (eculizumab) You have done well to manage your PNH with Soliris. Living with a rare disease, like PNH, can be challenging, but by sticking with your Soliris therapy, you are doing a lot to help
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationComment devenir CCA en un WE? HPN aplasie médullaire
Comment devenir CCA en un WE? HPN aplasie médullaire Régis Peffault de Latour, MD, PhD Saint Louis Hospital, Paris; regis.peffaultdelatour@sls.aphp.fr AIH 27 Septembre 2014 Paroxysmal Nocturnal Hemoglobinuria
More informationHemolytic Anemia. Hemolytic Anemia Classification Intracorpuscular Defects. Hemolytic Anemia Classification
Hemolytic Anemia Fletcher A. Miller, Jr, MD Mayo Clinic Rochester Valve Related Hemolysis Case Based presentation Shortened survival of red blood cells due to premature destruction Typical RBC lifespan
More informationCase Report Recurrent and Progressive Abdominal Pain and Enteritis in a Japanese Patient with Paroxysmal Nocturnal Hemoglobinuria
Case Reports in Hematology, Article ID 310750, 4 pages http://dx.doi.org/10.1155/2014/310750 Case Report Recurrent and Progressive Abdominal Pain and Enteritis in a Japanese Patient with Paroxysmal Nocturnal
More informationNew Insights into Paroxysmal Nocturnal Hemoglobinuria
New Insights into Paroxysmal Nocturnal Hemoglobinuria Robert A. Brodsky Johns Hopkins University School of Medicine, Division of Hematology, Baltimore, MD Correspondence: Robert A. Brodsky, MD, Ross Research
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More informationInternational PNH Interest Group Meeting Dec 8, 2017
International PNH Interest Group Meeting Dec 8, 2017 APL-2 is a C3 inhibitor APL-2 Subcutaneous for PNH, AIHA & CDN Intravitreal for GA Peptides of the APL-2 family bind to a pocket of C3 and inhibit activation*
More informationAAMDSIF_ Page 1 of 30 Angie Onofre, Dr. Amy DeZern
AAMDSIF_032216 Page 1 of 30 Angie Onofre: This is a pre-recorded presentation, so the presenter will not be taking any questions. However, all questions asked during the live presentation, along with answers,
More informationCoding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7
TABLE OF CONTENTS Product Variations.... 1 Policy Statement.... 1 Related Policies.... 4 Policy Guidelines..... 4 Coding.... 5 Benefit Application........ 5 Description of Services..... 6 Clinical Evidence.......
More informationParoxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis
September 2013 Volume 11, Issue 9, Supplement 13 Paroxysmal Nocturnal Hemoglobinuria: Pathogenesis, Testing, and Diagnosis Plus a Case Report and a Q&A on the Role of the Hematopathologist Vivek R. Sharma,
More informationTheme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -
Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects - Professor Yutaka YATOMI, M.D., Ph.D., The Department of Clinical Laboratory Medicine,
More informationNew phase 2 Clinical Trial Enrolling Now
New phase 2 Clinical Trial Enrolling Now Warm Autoimmune Hemolytic Anemia (waiha) and Cold Agglutinin Disease (CAD) Designed for patients Age 18 or older With a primary diagnosis of waiha who had a recurrence,
More informationAnemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017
Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationErythrocyte sedimentation rate. Hemolysis. Blood groups. Erythrocyte sedimentation rate (ESR)
Erythrocyte sedimentation rate. Hemolysis. Blood groups. Erythrocyte sedimentation rate (ESR) Definition: The erythrocyte sedimentation rate (ESR), also called a sedimentation rate, sed rate, or Biernacki
More informationAnemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi
Anemia (3).ms4.25.Oct.15 Hemolytic Anemia Abdallah Abbadi Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k, retics 12%, LDH
More informationParoxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine Phillip Scheinberg, Michael Marte, Olga Nunez, and Neal S. Young
More informationHematology: Challenging Cases with Your Participation COPYRIGHT
Hematology: Challenging Cases with Your Participation Reed E. Drews, MD Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Question 1 Question 1 64-year-old man is evaluated during
More informationMore Than Meets the Eye
The new england journal of medicine clinical problem-solving More Than Meets the Eye John S. Nguyen, M.D., Spyridon S. Marinopoulos, M.D., Bimal H. Ashar, M.D., and John A. Flynn, M.D. In this Journal
More informationAverage adult = 8-10 pints of blood. Functions:
Average adult = 8-10 pints of blood Functions: Transports nutrients, oxygen, cellular waste products, and hormones Aids in distribution of heat Regulates acid-base balance Helps protect against infection
More informationJunfeng Wang 12/10/2010
Paroxysmal Nocturnal Hemoglobinuria. Junfeng Wang 12/10/2010 31 Year Old Female with 11-year History of PNH In 1989, she presented with bleeding & pancytopenia. BM x2 showed AA. Cytogenetic ti was normal.
More information9/23/2018. Investigation of Hemolysis in the Clinical Laboratory. Objectives. What is hemolysis?
Investigation of Hemolysis in the Clinical Laboratory Jason Anderson, MPH, MT(ASCP) Field Product Specialist Objectives 1. Define hemolysis. 2. Distinguish between intrinsic and extrinsic hemolysis 3.
More informationALXN 1210 for paroxysmal nocturnal haemoglobinuria first line
NIHR Innovation Observatory Evidence Briefing: November 2017 ALXN 1210 for paroxysmal nocturnal haemoglobinuria first line NIHRIO (HSRIC) ID: 12793 NICE ID: 9701 LAY SUMMARY Paroxysmal nocturnal haemoglobinuria
More informationHow to diagnose myeloproliferative neoplasms and PNH in vascular diseases of the liver Valerio De Stefano
How to diagnose myeloproliferative neoplasms and PNH in vascular diseases of the liver Valerio De Stefano Institute of Hematology, Catholic University School of Medicine, Academic Hospital A. Gemelli,
More informationBaseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
ARTICLES Paroxysmal Nocturnal Hemoglobinuria Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry Hubert Schrezenmeier, 1 Petra Muus,
More informationNew phase 2 Clinical Trial Enrolling Now
New phase 2 Clinical Trial Enrolling Now Warm Autoimmune Hemolytic Anemia (waiha) and Cold Agglutinin Disease (CAD) Designed for patients Age 18 or older With a primary diagnosis of waiha who had a recurrence,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationSoliris (eculizumab): Paroxysmal nocturnal haemoglobinuria (PNH) Patient/Parent information brochure
Soliris (eculizumab): Paroxysmal nocturnal haemoglobinuria (PNH) Patient/Parent information brochure CONTENTS PAGE GLOSSARY TERMS INTRODUCTION WHAT IS SOLIRIS? FREQUENTLY ASKED QUESTIONS WHAT ARE THE SAFETY
More informationCHERYL KOVALSKI, DO FACOI NO DISCLOSURES ACOI BOARD REVIEW 2018
CHERYL KOVALSKI, DO FACOI NO DISCLOSURES ACOI BOARD REVIEW 2018 ANEMIA Hemoglobin
More informationNon-immune acquired haemolytic anaemias. Dr.Maysem
Non-immune acquired haemolytic anaemias Dr.Maysem Causes of Non-immune acquired haemolytic anaemias. Infections Infections can cause haemolysis in a variety of ways: -They may precipitate an acute haemolytic
More informationThe Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)
The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011) By Gene Gulati, Ph.D., SH(ASCP) Conflict of Interest None Plan for the Course Review blood smears,
More informationHEMOLY L TIC AN A EMIA
HEMOLYTIC ANEMIA In a healthy person, a red blood cell survives 90 to 120 days in the circulation, so about 1% of human red blood cells break down each day. The spleen (part of the reticulo-endothelial
More informationExtra Notes 3. Warm. In the core (center) of the body, where the temperature is 37 C.
Extra Notes 3 *The numbers of the slides are according to the last year slides. Slide 33 Autoimmune hemolytic anemia : Abnormal circulating antibodies that target normal antigen on the RBC and cause lysis.
More informationpersistent low-level PNH that predated and possibly contributed to the development
Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes Why? Why? Why? Commentary See related article, pages 689 696. Neal S. Young and Jaroslaw P. Maciejewski
More informationApellis Company Presentation March 2019
Apellis Company Presentation March 219 Forward looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that
More informationThe primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
More informationRationale for RBC Transfusion in SCD
Rationale for RBC Transfusion in SCD Dilution of HgbS-containing RBCs via the addition of HgbA-containing cells from the blood of normal donors Suppression of erythropoietin release caused by the rise
More informationPrevalence and prognosis of paroxysmal nocturnal haemoglobinuria and the clinical and costeffectiveness
UNIVERSITY OF BIRMINGHAM Prevalence and prognosis of paroxysmal nocturnal haemoglobinuria and the clinical and costeffectiveness of eculizumab Martin Connock, Dechao Wang, Anne Fry-Smith, & David Moore
More informationChapter 16: Circulation
Chapter 16: Circulation Section 1: The Body s Transport System Beating Heart Cardiac muscle is Striated and branched Under involuntary control by the brain stem Functions of the Cardiovascular System 1.
More informationDone by :Aseel Twaijer & Laith Sorour Hemolytic Anemias
Hemolytic Anemias Hemolytic anemias share the following features: - A shortened red cell life < 120 days - Elevated erythropoietin levels (compensatory increase in erythropoiesis) - Accumulation of hemoglobin
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationRISING HEALTHCARE COSTS: A Deeper Look Into. Catastrophic Claims by Stacy Borans, MD, Chief Medical Officer, Advanced Medical Strategies
RISING HEALTHCARE COSTS: A Deeper Look Into Catastrophic Claims by Stacy Borans, MD, Chief Medical Officer, Advanced Medical Strategies 4 July 2013 The Self-Insurer Self-Insurers Publishing Corp. All rights
More information? Medical mystery? A case report
? Medical mystery? A case report N. Boeckx, MD, PhD 03-10-2017 Case report 34 year male Medical history (Peru) 2014: anemia (Hb 7-8 g/dl) => endoscopy: negative, R/ iron April 2015: acute cholecystitis
More information